

Datasheet for ABIN7174442  
**anti-UBE2D3 antibody (AA 1-147)**[Go to Product page](#)

## 1 Image

## Overview

Quantity:	100 µg
Target:	UBE2D3
Binding Specificity:	AA 1-147
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This UBE2D3 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA

## Product Details

Immunogen:	Recombinant Human Ubiquitin-conjugating enzyme E2 D3 protein (1-147AA)
Isotype:	IgG
Cross-Reactivity:	Human, Rat
Purification:	>95%, Protein G purified

## Target Details

Target:	UBE2D3
Alternative Name:	UBE2D3 ( <a href="#">UBE2D3 Products</a> )
Background:	Background: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes \\Lys-11\\, as well as \\Lys-48\\-linked

## Target Details

polyubiquitination. Cooperates with the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation. Acts as an initiator E2, priming the phosphorylated NFKBIA target at positions '\\Lys-21\\' and/or '\\Lys-22\\' with a monoubiquitin. Ubiquitin chain elongation is then performed by CDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. Acts also as an initiator E2, in conjunction with RNF8, for the priming of PCNA. Monoubiquitination of PCNA, and its subsequent polyubiquitination, are essential events in the operation of the DNA damage tolerance (DDT) pathway that is activated after DNA damage caused by UV or chemical agents during S-phase. Associates with the BRCA1/BARD1 E3 ligase complex to perform ubiquitination at DNA damage sites following ionizing radiation leading to DNA repair. Targets DAPK3 for ubiquitination which influences promyelocytic leukemia protein nuclear body (PML-NB) formation in the nucleus. In conjunction with the MDM2 and TOPORS E3 ligases, functions ubiquitination of p53/TP53. Supports NRDP1-mediated ubiquitination and degradation of ERBB3 and of BRUCE which triggers apoptosis. In conjunction with the CBL E3 ligase, targets EGFR for polyubiquitination at the plasma membrane as well as during its internalization and transport on endosomes. In conjunction with the STUB1 E3 quality control E3 ligase, ubiquitinates unfolded proteins to catalyze their immediate destruction (By similarity).

Aliases: E2(17)KB3 antibody, MGC43926 antibody, MGC5416 antibody, PRO2116 antibody, UB2D3\_HUMAN antibody, UBC 4/5 antibody, UBC4/5 antibody, UBC4/5 homolog yeast antibody, UBC4/5, S. cerevisiae, homolog of antibody, UBCH 5C antibody, UBCH5C antibody, Ube2d3 antibody, Ubiquitin carrier protein antibody, Ubiquitin carrier protein D3 antibody, Ubiquitin conjugating enzyme E2 17 kDa 3 antibody, Ubiquitin conjugating enzyme E2 D3 antibody, Ubiquitin conjugating enzyme E2D 3 (homologous to yeast UBC4/5) antibody, Ubiquitin conjugating enzyme E2D 3 (UBC4/5 homolog yeast) antibody, Ubiquitin conjugating enzyme E2D 3 antibody, Ubiquitin protein ligase D3 antibody, Ubiquitin-conjugating enzyme E2 D3 antibody, Ubiquitin-conjugating enzyme E2(17)KB 3 antibody, Ubiquitin-conjugating enzyme E2-17 kDa 3 antibody, Ubiquitin-protein ligase D3 antibody

UniProt: [P61077](#)

Pathways: [Activation of Innate immune Response](#), [Toll-Like Receptors Cascades](#)

## Application Details


Application Notes: Recommended dilution: WB:1:500-1:5000,

Restrictions: For Research Use only

Handling

Format:	Liquid
Buffer:	Preservative: 0.03 % Proclin 300 Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	-20 °C,-80 °C
Storage Comment:	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Images



Western Blotting

**Image 1.** Western Blot Positive WB detected in: HeLa whole cell lysate, Rat skeletal muscle tissue All lanes: UBE2D3 antibody at 4.8 µg/mL Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 17 kDa Observed band size: 17 kDa